Diversified Healthcare Azioni (NASDAQ: DHC)

Ultime notizie per Diversified Healthcare (NASDAQ:DHC) Azioni

Diversified Healthcare

Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. It operates through two segments: Office Portfolio and SHOP. The office portfolio includes medical office properties leased to medical-related businesses and life sciences properties. The SHOP segment runs communities that offer multiple types of residential care, ranging from independent living to nursing services. DHT operates across the United States and the majority of its revenue derives from rents and medical programs. Majority of revenue is from SHOP segment.

Hand,Choosing,Wooden,House,Model,,Mortgage,And,Real,Estate,Property

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

DOUG

Il settore immobiliare accelera, con alcuni titoli che registrano performance sorprendenti e attirano l&#39;attenzione degli investitori.

Crescita nel real estate: i titoli che stanno sorprendendo Wall Street

Diversified Healthcare Trust - Common Shares of Beneficial Interest

Diversified Healthcare Trust

DHC ACQUISITION CORP UNIT 1 CL A & 1/3 WT EXP

DIAMONDHEAD CASINO CORP by Diamondhead Casino Corp.

Diamondhead Casino Corp

DATA HORIZON CO LTD by DATA HORIZON CO LTD.

Diversified Healthcare Trust - 5.625% Senior Notes due 2042

Diversified Healthcare Trust - 6.25% Senior Notes Due 2046

Oncolytics Biotech&#xAE;&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Jared Kelly as Chief Executive Officer and a member of its Board of Directors.
<img src="https://mma.prnewswire.com/media/2408622/5364608/Oncolytics_Biotech_Inc_Logo.jpg" alt="Oncolytics Biotech Inc Logo" />
Mr. Kelly is a successful biotech executive who has proven expertise in transformative deals and corporate strategy. Most recently, he played a central role in orchestrating the sale of&nbsp;Ambrx Biopharma to Johnson &amp; Johnson for $2 billion. Prior to Ambrx, he advised multiple leading-edge biotech companies on M&amp;A and licensing transactions at highly respected law firms, including Lowenstein Sandler LLP and Kirkland &amp; Ellis LLP. He is a JD and LLM graduate of Georgetown Law.
"Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of Oncolytics' Board of Directors and outgoing Interim CEO. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors."
Mr. Kelly added, "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients. With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders."
Pelareorep, an intravenously-administered immunotherapeutic agent, has been granted FDA Fast Track designation by the U.S. Food and Drug Administration (FDA) in metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC). It has delivered compelling results in mPDAC, a high-value indication with significant unmet need. In Phase 1 and 2 trials involving more than 140 mPDAC patients, pelareorep has delivered a &gt;60% objective response rate in tumor evaluable patients in the most recent study, which is more than double the benefit observed in historical control trials, and, separately, two-year survival rates 4-6 times those observed in control patients or against the benchmark in prior studies.
In mBC, pelareorep recorded a meaningful survival benefit in two randomized Phase 2 studies of over 100 combined mBC patients, IND-213 and BRACELET-1. Phase 2 objective response rate data in second-line or later unresectable squamous cell carcinoma of the anal canal (SCCA) patients continue to exceed historical data for treatment with a checkpoint inhibitor alone. These consistent efficacy signals, in combination with multiple chemotherapies and checkpoint inhibitors, uniquely position pelareorep as a high-potential asset for further development in-house and/or through strategic partnerships. Pelareorep also has a well-defined and favorable safety profile based on data from &gt;1,100 patients across multiple tumor types.
As a material inducement to Mr. Kelly's appointment as Chief Executive Officer, and in accordance with NASDAQ Listing Rule 5635(c)(4), Mr. Kelly has been awarded an initial stock option grant exercisable for 2,850,000 shares with an exercise price of CAD$0.57, vesting equally over three years. He also received a performance-based stock option grant exercisable for 1,900,000 shares with an exercise price of CAD$0.57, which will vest upon the achievement of certain financing objectives. All stock option grants have a term of 5 years from the date of grant. The Company also granted Mr. Kelly restricted stock units, which will entitle him to receive that number of Common Shares equal to 2% of the Company's then outstanding common shares upon the Company entering into a definitive agreement for certain transactions providing for the acquisition of the Company or the exclusive license of pelareorep. Each of these awards is intended to align Mr. Kelly's long-term incentives with the creation of shareholder value.

Management

ONCY

TSX:ONC

Oncolytics Names Jared Kelly CEO, Wayne Pisano Steps Down After Guiding Immunotherapy Progress

Offerings

ETSY

Etsy Announces Proposed Private Offering Of $650M Of Convertible Senior Notes; Expects To Use Up To $175M Of The Net Proceeds From The Offering To Repurchase Shares Of Common Stock And The Remainder Of Net Proceeds For General Corporate Purposes

Earnings

CHWY

Chewy Q1 2025 Adj. EPS $0.35 Beats $0.34 Estimate, Sales $3.12B Beat $3.08B Estimate

IONS

Ionis Doses First Patient In Phase 3 Study Of ION582 For Angelman Syndrome

-Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement-
-Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS-
NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits,&nbsp;today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare.

HSDT

HSDTW

Helius Medical Technologies Announces Authorized Claim For Payment For PoNS Device From Aetna Healthcare.

Travere Therapeutics, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) today announced that the Company will present three abstracts on the effect of FILSPARI (sparsentan) in rare kidney disease at the upcoming International Podocyte Conference in Hamburg, Germany, June 10-13, 2025.
The Company will present new data evaluating biomarkers of disease progression in IgA nephropathy (IgAN) from the Phase 2 SPARTAN Study showing rapid and sustained reductions in urinary BAFF and sC5b9 as well as reductions in proinflammatory and profibrotic biomarkers after starting FILSPARI, suggesting disease-modifying activity.

TVTX

Travere To Present New Kidney Drug Data At Global Conference, Shows FILSPARI May Slow Disease Progression

Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) reported quarterly earnings of $0.09 per share which met the analyst consensus estimate. This is a 25 percent decrease over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $1.35 billion which met the analyst consensus estimate. This is a 0.52 percent decrease over sales of $1.36 billion the same period last year.

VSCO

Victoria's Secret Q1 Adj. EPS $0.09, Sales $1.35B, Both Inline

Financing

Nouveau Monde Graphite Inc Says Received Over $1B In Letters Of Interest For Project Debt Financing Towards Phase-2 Matawinie Mine And Bécancour Battery Material Plant

GENI

NFL And Genius Sports Extend Collaboration, Powering Next-Gen Betting And Broadcast Tools

PAYS

Paysign Completes Transition of 123 Plasma Centers Ahead of Schedule, Boosting Growth Momentum

HC Wainwright &amp; Co. analyst Emily Bodnar assumes Artiva Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTV#NASDAQ">ARTV</a>) with a Buy rating and announces Price Target of $12.

Price Target

Initiation

Analyst Ratings

ARTV

HC Wainwright & Co. Assumes Artiva Biotherapeutics at Buy, Announces Price Target of $12

New design demonstrates end-to-end energy-efficient cooling and power to support densities up to 142kW per rack
COLUMBUS, Ohio, June 11, 2025 /PRNewswire/ -- Vertiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>), a global leader in critical digital infrastructure, announced its energy-efficient <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4446615-1&amp;h=406050614&amp;u=https%3A%2F%2Fwww.vertiv.com%2Fen-us%2Fsolutions%2Fai-hub%2Fdesign%2F%23%2FReference-design&amp;a=142kW+cooling+and+power+reference+architecture">142kW cooling and power reference architecture</a>&nbsp;for the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4446615-1&amp;h=306546154&amp;u=https%3A%2F%2Fwww.nvidia.com%2Fen-us%2Fdata-center%2Fgb300-nvl72%2F&amp;a=NVIDIA+GB300+NVL72">NVIDIA GB300 NVL72</a> platform. In addition to fully integrated end-to-end cooling and power strategies for this next generation platform, the reference architecture unlocks a new era of infrastructure design by shifting from traditional buildouts. Vertiv solutions are available as <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4446615-1&amp;h=1895570019&amp;u=https%3A%2F%2Fdeveloper.nvidia.com%2Fomniverse%2Fsimready-assets&amp;a=SimReady%E2%84%A2+3D+assets">SimReady&#x2122; 3D assets</a> in the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4446615-1&amp;h=1667340227&amp;u=https%3A%2F%2Fbuild.nvidia.com%2Fnvidia%2Fdigital-twins-for-ai-factories&amp;a=NVIDIA+Omniverse+Blueprint+for+AI+factory+design+and+operations">NVIDIA Omniverse Blueprint for AI factory design and operations</a>.&nbsp;The reference architecture can be customized for bespoke data center designs to dramatically reduce planning times and reduce risk during the buildout process. &nbsp;

NVDA

Vertiv Announces 142kW Cooling And Power Reference Architecture For NVIDIA GB300 NVL72 Platform

Guidance

CGNT

Cognyte Software Raises FY2026 Adj EPS Guidance from $0.16 to $0.19 vs $0.16 Est; Raises FY2026 Sales Guidance from $384.16M-$399.84M to $387.10M-$402.90M vs $391.44M Est

Canadians are boycotting the United States as a tourist destination in record numbers, new data shows.
What Happened: According to Statistics Canada, car travel by Canadians into the U.S. fell 38% in May compared to the same time last year, while air travel dropped 24%. Forbes <a href="https://www.forbes.com/sites/suzannerowankelleher/2025/06/10/canadian-tourists-to-us-down-nearly-40-in-may-new-data-says/">notes</a> that this marks the fifth straight month of steep year-over-year declines, on track with a trend that began earlier in 2025.
Canadian visitors historically make up around a quarter of all foreign arrivals in the US.
The U.S. Travel Association warned earlier that even a 10% fall in Canadian tourism could cost $2.1 billion and threaten 140,000 jobs in hospitality and associated sectors. With losses now exceeding those projections by two to four times, the economic fallout could be significant.
"Given trends in our pre-Inauguration forecast, we were expecting a 9% increase in international visitors this year," said Adam Sacks, president of Tourism Economics. "So the full way to appreciate the loss is relative to the growth that would have happened based on the ongoing recovery that was expected."
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45877591/elon-musk-says-he-regrets-war-of-words-with-trump-went-too-far">Elon Musk Says He &#8216;Regrets&#8217; War Of Words With Trump: &#8216;Went Too Far&#8217;</a>
Why It Matters: The U.S. is likely to face a major drop in global tourism revenue, with the World Travel &amp; Tourism Council (WTTC) projecting a $12.5 billion dip in international visitor spending this year.
According to the council's latest Economic Impact Research, foreign spending in the U.S. is estimated to fall to just under $169 billion in 2025, down from $181 billion in 2024
The U.S. holds the world's largest travel and tourism market, but stands out as the only country among 184 economies analyzed by WTTC and Oxford Economics forecasted to suffer a decline in international tourism spending this year.
The sharp drop in Canadian tourists originates from a boycott call issued by former Prime Minister Justin Trudeau, who advised citizens to avoid U.S. vacations after President Donald Trump referred to Canada as <a href="https://www.benzinga.com/25/02/43582659/trump-says-canada-much-better-off-being-the-51st-state-the-border-with-us-is-just-a-line">"the 51st state"</a> and <a href="https://www.benzinga.com/news/25/03/44253100/trump-slaps-50-tariff-on-canadian-steel-aluminum-threatens-auto-industry">floated new tariffs</a>.
If current trends sustain, the U.S. could lose more than $21 billion in travel-related exports by year's end.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45877836/world-bank-slashes-global-growth-forecast-to-lowest-since-1960s-amid-trump-tariffs-if-the-right-policy-actions-are-taken">World Bank Slashes Global Growth Forecast To Lowest Since 1960s Amid Trump Tariffs: &#8216;If The Right Policy Actions Are Taken&#8230;&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Travel

US To Lose $21 Billion In Travel-Related Exports As Canadian Tourist Boycott Threatens 140,000 Thousand Jobs: Report

Significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, measures of disease activity and quality of life at Week 16 in POETYK PsA-1
New data from POETYK PsA-2 trial demonstrated that meaningful clinical responses continued to improve and outcomes were maintained through Week 52
Sotyktu demonstrated safety consistent with the established clinical profile and was well tolerated in both studies, with no new safety signals
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54271967&amp;newsitemid=20250610213248&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=9b6ef596309f7eebddfadc2dc480b6d2">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced positive data from the pivotal Phase 3 POETYK PsA-1 trial (IM011-054) evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) who were not previously treated with a biologic disease-modifying antirheumatic drug (bDMARD). The trial met its primary endpoint, with a significantly greater proportion of patients treated with Sotyktu achievingACR20 response (at least a 20 percent improvement in signs and symptoms of disease) compared with placebo at Week 16 (54.2% versus 34.1%, respectively; p&lt;0.0001). The safety profile of Sotyktu through 16 weeks of treatment was consistent with what has been reported throughout the clinical trial programs for Sotyktu, including the Phase 3 POETYK PsA-2 trial and the Phase 3 moderate-to-severe plaque psoriasis (PsO) clinical trials.
The data for POETYK PsA-1 are being presented as a late-breaking abstract (#LB0001) at the European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain, taking place June 11-14, 2025.

Bristol Myers Squibb Announces Phase 3 POETYK PsA-1 Trial Met Primary Endpoint For Sotyktu In Psoriatic Arthritis

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">MannKind Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>)</h3>
<ul class="wp-block-list">
<li>MannKind will highlight data from recent pediatric and adult studies of inhaled insulin at American Diabetes Association&#8217;s 85th Scientific Sessions. The company's stock fell around 19% over the past month and has a <a href="https://www.benzinga.com/quote/MNKD">52-week low of $3.89</a>.</li>
<li>RSI Value: 29.1</li>
<li>MNKD Price Action: Shares of MannKind fell 10.3% to close at $3.92 on Tuesday.</li>
<li>Edge Stock Ratings: 16.33 Momentum score with Value at 24.26. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/mnkd"><img loading="lazy" decoding="async" width="432" height="162" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11065518/image-154.png" alt="" class="wp-image-945947" style="width:317px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11065518/image-154.png 432w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11065518/image-154-300x113.png 300w" sizes="(max-width: 432px) 100vw, 432px" /></a></figure>
<h3 class="wp-block-heading">SS Innovations International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On May 14, SS Innovations posted a first-quarter loss of 3 cents per share on sales of $5.10 million. Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, said, &#8220;In the first quarter of 2025, we achieved record quarterly revenue of $5.1 million, up 40.8% from $3.6 million in the first quarter of 2024, driven by higher unit sales of our innovative, cutting-edge SSi Mantra 3 surgical robotic system to leading healthcare facilities in India and abroad." The company's stock fell around 59% over the past month and <a href="https://www.benzinga.com/quote/SSII">has a 52-week low</a> of $4.10.</li>
<li>RSI Value: 22.5</li>
<li>SSII Price Action: Shares of SS Innovations International fell 8.3% to close at $4.20 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0611">SSII stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0611"><img loading="lazy" decoding="async" width="917" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11065629/image-155.png" alt="" class="wp-image-945948" style="width:575px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11065629/image-155.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11065629/image-155-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11065629/image-155-768x706.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">INVO Fertility Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>)</h3>
<ul class="wp-block-list">
<li>On May 20, INVO Fertility posted a first-quarter loss of $12.53 per share, versus a year-ago loss of $7.55 per share. &#8220;After announcing the divestiture of a majority stake in NAYA TX, we&#8217;ve sharpened our focus on our core mission as a fertility company, poised to seize opportunities in a dynamic market bolstered by supportive policy shifts of the current administration supporting developments that underscore the importance of fertility care,&#8221; commented Steve Shum, CEO of INVO Fertility. &#8220;This strategic move aligns with the ongoing decline in U.S. fertility rates and growing demand for accessible fertility solutions, reinforcing our commitment to broadening care for patients in need.&#8221; The company's stock fell around 33% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/IVF">low of $1.37</a></li>
<li>RSI Value: 26</li>
<li>IVF Ltd Price Action: Shares of INVO Fertility fell 6% to close at $1.42 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0611">IVF shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0611"><img loading="lazy" decoding="async" width="900" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11065728/image-156.png" alt="" class="wp-image-945951" style="width:501px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11065728/image-156.png 900w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11065728/image-156-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11065728/image-156-768x721.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45858699/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-q2">Top 2 Tech And Telecom Stocks You May Want To Dump In Q2</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

MNKD

SSII

Top 3 Health Care Stocks That May Rocket Higher This Quarter

Earnings Beats

Cognyte Software Q1 Adj. EPS $0.07 Beats $0.01 Estimate, Sales $95.55M Beat $93.96M Estimate

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) with a Buy and maintains $13 price target.

Reiteration

PDSB

HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $13 Price Target

Accenture Partners With NVIDIA To Launch AI Refinery In Europe, Advancing Sovereign And Agentic AI Capabilities

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Buy and maintains $720 price target.

Comments

Diversified Healthcare

Notizie

Ultime notizie per Diversified Healthcare (NASDAQ:DHC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO